OTC : ORINY

Orion Oyj

$43.016 USD

$0 (0.0%)

Volume
3
Average Volume
172
Market Capitalization
$24.22B
P/E Ratio
18.97
Dividend Yield
2.17%
Price Target
Year High
$43.22
Year Low
$30.89
Day High
—
Day Low
—
Payout Ratio
$0.41
Current Ratio
$2.64
Company Overview

OTC

Liisa Hurme

Drug Manufacturers - General

Healthcare

ORINY

3943

FI

USD

https://www.orionpharma.com

358 10 4261

68628Y104

N/A

Liquidity Metrics

0.10

2.64

1.48

0.29

0.41

Sales & Valuation

$1.89B

5.41

8.78

28.65

1.38

Profitability

$0.86

$480.55M

28.54%

35.80%

50.02%

31.34%

P/E Metrics

18.97

0.34

0.34

Analyst Price Target & Rating

Neutral

3/5

3 Analysts

%

Financial Health Scores

24.74

7/9

$744.8M

$1.87B

$604.7M

$722.68M

Key Metrics (TTM)

$11.04B

5.37

14.04

2.64

50.02%

40.71%

5.31%

3.52%

$29.06

313 days

Company Executives
Name Title
Outi Vaarala Executive VP of Research & Development and Member of the Exe. Mgmt. Board
Mikko Kemppainen General Counsel, Secretary to the Board & Member of Executive Management Board
Niclas Lindstedt EMBA Executive VP of Animal Health & Member of the Exe. Mgmt. Board
Rene Lindell Chief Financial Officer & Member of Group Executive Management Board
Julia Irene Macharey Executive VP of People & Culture & Member of Management Board
Satu Ahomäki Executive VP of Generics and Consumer Health & Member of the Exe. Mgmt. Board
Liisa Hurme President, Chief Executive Officer & Chairman of Executive Management Board
Berkeley Vincent Executive Vice President of Innovative Medicines & Member of Management Board
Hao Pan Executive VP of the Branded Products & Member of the Exe. Mgmt. Board
Juhani Kankaanpaa Executive VP of Global Operations & Member of Executive Management Board
Poll Results

No votes yet today — be the first to share your view!

About Orion Oyj (OTC:ORINY) Stock

Orion Oyj is a Finnish pharmaceutical company specializing in the creation, production, and commercialization of medicines for both human and animal health, as well as the active components (APIs) essential for drug formulation. Its operations extend across Finland, the Nordic region, wider Europe, North America, and various international markets. The company's diverse product portfolio encompasses both prescribed medications and over-the-counter (OTC) healthcare solutions. This includes notable offerings such as Nubeqa for prostate cancer therapy; Dexdor and Precedex, utilized as sedatives in intensive care settings; Stalevo and Comtess/Comtan addressing Parkinson's disease; Simdax for acute heart failure decompensation; and Fareston for breast cancer management. Additionally, a range of ... Easyhaler devices—like Salmeterol/fluticasone, Budesonide/formoterol, Formoterol, Budesonide, Beclomet, and Buventol—are provided for managing asthma and chronic obstructive pulmonary disease (COPD). Beyond human medicine, the firm supplies a suite of veterinary medications, including products such as Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie. It also produces APIs for both proprietary and generic pharmaceutical products and offers specialized contract manufacturing capabilities. Furthermore, Orion Oyj distributes veterinary medicines manufactured by other global pharmaceutical entities. Its clientele spans a broad spectrum of healthcare stakeholders, from specialist and general physicians, veterinarians, and pharmacists to hospitals, healthcare centers, clinics, laboratories, and directly to consumers who own pets. Strategic alliances include a collaboration with Propeller Health aimed at integrating its Easyhaler® product range for asthma and COPD management with digital health solutions. Additionally, it holds a research collaboration and licensing deal with Alligator Bioscience AB (publ) focused on pioneering novel bispecific antibody-based cancer treatments. Established in 1917, Orion Oyj maintains its corporate headquarters in Espoo, Finland.

Orion Oyj (ORINF) Q1 2026 Earnings Call Transcript

2026-04-23 09:31:34

Orion Oyj (ORINF) Q1 2026 Earnings Call Transcript

Frequently Asked Questions

What is the current Orion Oyj (ORINY) stock price?

Orion Oyj(OTC:ORINY) stock price is $43.016 in the last trading session. During the trading session, ORINY stock reached the peak price of $43.22 while $30.89 was the lowest point it dropped to. The percentage change in ORINY stock occurred in the recent session was 0.0% while the dollar amount for the price change in ORINY stock was $0.

ORINY's industry and sector of operation?

The OTC listed ORINY is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.

Who are the executives of ORINY?

Outi Vaarala | Executive VP of Research & Development and Member of the Exe. Mgmt. Board
Mikko Kemppainen | General Counsel, Secretary to the Board & Member of Executive Management Board
Niclas Lindstedt EMBA | Executive VP of Animal Health & Member of the Exe. Mgmt. Board
Rene Lindell | Chief Financial Officer & Member of Group Executive Management Board
Julia Irene Macharey | Executive VP of People & Culture & Member of Management Board

How many employees does ORINY have?

Number of ORINY employees currently stands at 3943. ORINY operates from Orionintie 1A, Espoo, UU 02200, FI.

Link for ORINY official website?

Official Website of ORINY is: https://www.orionpharma.com

How do I contact ORINY?

ORINY could be contacted at phone #358 10 4261 and can also be accessed through its website. ORINY operates from Orionintie 1A, Espoo, UU 02200, FI.

How many shares of ORINY are traded daily?

The average number of ORINY shares traded daily for last 3 months was 172.

What is the market cap of ORINY currently?

The market value of ORINY currently stands at $24.22B with its latest stock price at $43.016